Thrombolytic therapy for pulmonary embolism

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Bi, Rong Dong ^a   Hao, Qiukui ^a   Yue, Jirong ^a   Wu, Taixiang ^a   Guan, Jian Liu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

*Thrombolytic therapy; Fibrinolytic agents *therapeutic use ; Heparin therapeutic use ; Humans; Pulmonary embolism *drug therapy ; Randomized controlled trials as topic

Indexed keywords

ALTEPLASE; HEPARIN; HYDROCORTISONE; STREPTOKINASE; TENECTEPLASE; UROKINASE; WARFARIN;

BLEEDING DISORDER; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; LOADING DRUG DOSE; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG RESISTANCE; LUNG SCINTISCANNING; MORTALITY; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION;

EID: 70049096613     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004437.pub3     Document Type: Review

References (72)

1. * Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al.PAIMS2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. Journal of the American College of Cardiology 1992;20(3):520-526
2. * Goldhaber SZ, Haire WD, Fekdstein ML, Miller M, Toltzis R, Smith JL, et al.Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. The Lancet 1993;341(8844):507-511
3. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. New England Journal of Medicine 2002;347(15):1143-1150
4. * Levine M, Hirsh J, Weitz J, Cruickshank M, Meemeh J, Turpie AG, et al.A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98(6):1473-1479
5. Arnesen BLH, Eie H, Hol R. A prospective study of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica Supplement 1978; Vol.621:15. (Pubitemid 9050670)
6. * Ly B, Arneson H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment ofmajor pulmonary embolism. Acta Medica Scandinavica 1978;203(6):465-470
7. Anonymous. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest 1990;97(3):528-533
8. * Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Thomas ML, et al.Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. British Medical Journal 1974;1(904):343-347
9. Anonymous. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA 1970;214(12):2163-2171
10. Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al.The urokinase pulmonary embolism trial. Circulation 1973;47(2 Supplement):7-21.
11. Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagulation & Fibrinolysis 1997;8(4):216-222
12. Anonymous. Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism. Archives des Maladies du Coeur et des Vaisseaux 1984;77(7):773-781
13. Bell WR, Simon TL, Stengle JM, Sherry S. The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation 1974;50(6):1070-1071
14. Bell WR. Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study. Thrombosis and Haemostasis 1976;35(1):57-69.
15. Bell WR. Thrombolytic therapy: differences between streptokinase and urokinase. Vascular Surgery 1977;11:378-383 (Pubitemid 8241487)
16. Charbonnier B, Raynaud P, Griguier P, Brochier M. [Potentializing effects of a defibrillating agent on therapeutic thrombolysis in pulmonary embolism]. Archives des Maladies du Coeur et des Vaisseaux 1984; Vol.77:1426.
17. De Takats G. The urokinase pulmonary embolism trial. American Journal of Surgery 1973;126(3):311-313
18. Dotter CT, Seamon AJ, Rosch J, Porter J. Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison. Vascular Surgery 1979;13(1):42-52. (Pubitemid 9170443)
19. Erkan L, Findik S, Atici AG, Uzun O. Thrombolytic therapy in massive pulmonary thromboembolism. European Respiratory Journal 2002; Vol.20:237s.
20. Francois G, Charbonnier B, Raynaud P, Garnier LF, Griguer P, Brochier M. Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. 67 cases. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):435-442 (Pubitemid 16104556)
21. Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989;95(5 Suppl):282S-9S.
22. * Goldhaber SZ. TPA versus urokinase in acute pulmonary embolism: Results of a randomized controlled trial. Vasa - Supplementum 1989;27:292-294
23. Goldhaber SZ, Kessler CM, Heit JA, Elliot CG. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. Journal of the American College of Cardiology 1992;20(1):24-30.
24. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: An international multicenter randomised trial. Chest 1994;106(3):718-724 (Pubitemid 24278871)
25. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al.Streptokinase and heparin versus heparin alone inmassive pulmonary embolism: A randomized controlled trial. Journal of Thrombosis & Thrombolysis 1995;2(3):227-229
26. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. American Journal of Cardiology 1998;82(8):966-970 (Pubitemid 28480783)
27. Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sashara AA, et al.Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. Journal of Laboratory Clinical Medicine 1978;92(5):721-729
28. Giuntini C, Marini C, Di Ricco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism. Giornale Italiano di Cardiologia 1984;14 Suppl 1:26-29 (Pubitemid 15088448)
29. * Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54(3):162-173
30. Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al.Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. European Heart Journal 1997;18(7):1141-1148 (Pubitemid 27271887)
31. Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al.Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. Journal of the American College of Cardiology 1998;31(5):1057-1063 (Pubitemid 28212506)
32. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al.Comparison of the effect of an intravenous infusion of urokinase or alteplase on total pulmonary resistance in acute massive pulmonary embolism. A European, multi-center, double-blind study. Intensivmedizin und Notfallmedizin 1992;29:339-347
33. * Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al.Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. Journal of the American College of Cardiology 1992;19(2):239-245
34. Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal 1971;763(2):681-684
35. Muhl D, Furedi R, Gecse K, Ghosh S, Falusi B, Bogar L, et al.Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagulation & Fibrinolysis 2007;18(7):661-667 (Pubitemid 47479417)
36. Ohayon J, Colle JP, Tauzin-Fin P, Lorient-Roudaut MF, Besse P. Hemodynamic course during fibrinolysis in severe pulmonary embolism. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):445-453 (Pubitemid 16104557)
37. Palla A, Pazzagli M, Manganelli D, DeNitto P, Marini C, Rossi G, et al.Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration 1997;64(1):50-53 (Pubitemid 27055455)
38. Pang BS, Wang C, Lu Y, Yang YH, Xing GH, Mao YL, et al.[Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism]. Zhonghua yi xue za zhi 2007;87:3074-3078
39. Prandoni P, Zambon G, Scatigna M, et al.Diagnostic approaches and results in the medical treatment of pulmonary thromboembolism. Minerva Medica 1985;76:1727-1737 (Pubitemid 16220559)
40. Saponjski JD, Saponjski MD, Vukcevic VP. Massive pulmonary embolism and thrombolysis in the first week after major surgery. European Respiratory Journal 2002;20(Suppl 38):239s.
41. Sasahara AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thrombosis et Diathesis Haemorrhagica 1975;33(3):464-476
42. * Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. New England Journal of Medicine 1980;303(15):842-845
43. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vascular Medicine 2000;5(2):91-95 (Pubitemid 30485303)
44. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994;106(3):712-717 (Pubitemid 24278870)
45. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al.Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. American Heart Journal 1999;138(7):39-44. (Pubitemid 29331118)
46. The Urokinase pulmonary embolism trial study group, Urokinase Streptokinase Embolism Trial. Phase II results. JAMA : the journal of the American Medical Association 1974;229:1606-1613
47. The UKEP Study Research Group. The UKEP Study: multicentre clinical trial on two local regimes of urokinase in massive pulmonary embolism. European Heart Journal 1987;8(1):2-10.
48. Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al.Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77(2):353-360 (Pubitemid 18060044)
49. Wang C. [The clinical features of 516 patients with acute pulmonary thromboembolism]. Zhonghua yi xue za zhi 2006;86(31):2161-2165
50. Yang D, Zhao G, Wu H, Zhou H, Ji Y, Zhang Z. Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism [Abstract]. European Respiratory Journal 2007;30:544s.
51. Agnelli G, Becattini C. Tenecteplase pulmonary embolism Italian study. http://clinicaltrials.gov/ct/show/NCT00222651?order=1 (accessed April 2009) 2005. [: NCT00222651]
52. Anon. PEITHO Pulmonary Embolism Thrombolysis Study. http:// clinicaltrials.gov/ct2/show/NCT00639743?term=thrombolysis&rank=14(accessed April 2009) 2008. [: NCT00639743]
53. Bottiger BW, Bohrer H, Bach A, Motsch J, Martin E. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 1994;28(1):45-54. (Pubitemid 24246121)
54. Browse NL, James DC. Streptokinase and pulmonary embolism. Lancet 1962;2:1039.
55. Chesterman CN, Biggs JC, Morgan J, Hickie JB. Streptokinase therapy in acute major pulmonary embolism. Medical Journal of Australia 1969;2(22):1096-1100
56. Genton E, Wolf P. Urokinase therapy in pulmonary thromboembolism. American Heart Journal 1968;76(5):628-637
57. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2(8606):293-298 (Pubitemid 18184967)
58. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.. Available from www.cochranehandbook.org. Wiley-Blackwell, 2008.
59. Hirsh J, McDonald IG, Hale GA, et al.Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism. Canadian Medical Association Journal 1971;104(6):488-491
60. Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation 1970;42(6):979-980
61. Konstantinides S, Geibel A, Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy?. Thrombosis and Haemostasis 1999;82(suppl 1):104-108 (Pubitemid 30093642)
62. Perlroth DJ, Sanders GD, Gould MK, Perlroth Daniella J, Sanders Gillian D, Gould Michael K. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Archives of Internal Medicine 2007;167(1):74-80. (Pubitemid 46072410)
63. Sasahara AA, Cannilla JE, Belko JS, Morse RL, Criss AJ. Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent. New England Journal of Medicine 1967;277(22):1168-1173
64. Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al.The urokinase pulmonary embolism trial: A national cooperative study. Circulation 1973;47(2 Supplement):7-21.
65. Sautter RD, Emanuel RA, Fletcher FW, Wenzel FJ, Matson JI. Urokinase for the treatment of acute pulmonary thromboembolism. JAMA 1967;202(3):215-218
66. Serra-Prat M, Jovell AJ, Aymerich M. Efficacy and safety of thrombolytic therapy in pulmonary embolism: meta-analysis of randomized controlled trials. Medicina Clinica 1999;112(18):685-689 (Pubitemid 29268670)
67. Stein PD, Alavi A, Athanasoulis C, Coleman RE, Froelich JW, Greenspan RH, et al.Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990;97(3):52833. (Pubitemid 20095563)
68. Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. New England Journal of Medicine 1967;277(22):1161-1167
69. Vander Sande J, Bossaert L, Brochier M, Charbonnier B, Serradigmini A, Elias A, et al.Thrombolytic treatment of pulmonary embolism with APSAC. European Respiratory Journal 1988;1(8):721-725 (Pubitemid 18251267)
70. Wu TX, Liu GJ. The concepts, design, practice and reports of allocation concealment and blinding. Chinese Journal of Evidence-Based Medicine 2007;7(3):222-225
71. Yamasawa F, Okada Y, Asano K, Mori M, Fujita H, Hasegawa N, et al.The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism. Internal Medicine 1992;31(7):885-888
72. Dong BR, Yue J, Liu GJ, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004437.pub2]